Stantec (TSE:STN – Get Free Report) (NYSE:STN) had its price objective upped by research analysts at CIBC from C$121.50 to C$134.00 in a research note issued on Friday,BayStreet.CA reports. CIBC’s price target would suggest a potential upside of 13.95% from the company’s previous close.
STN has been the subject of several other research reports. Stifel Nicolaus boosted their price target on shares of Stantec from C$130.00 to C$145.00 in a report on Friday, October 4th. BMO Capital Markets upped their target price on shares of Stantec from C$135.00 to C$138.00 in a research report on Friday, December 6th. Canaccord Genuity Group raised their price target on shares of Stantec from C$125.00 to C$135.00 in a research note on Monday, November 11th. Finally, Scotiabank upgraded Stantec to a “strong-buy” rating in a research report on Friday, October 25th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Stantec currently has a consensus rating of “Moderate Buy” and a consensus target price of C$129.50.
Get Our Latest Stock Analysis on STN
Stantec Trading Down 0.7 %
Insider Buying and Selling at Stantec
In other Stantec news, Director Vito Culmone bought 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were acquired at an average cost of C$121.49 per share, for a total transaction of C$485,960.00. 0.27% of the stock is currently owned by corporate insiders.
Stantec Company Profile
Stantec Inc provides professional services in the areas of infrastructure and facilities to the public and private sectors in Canada, the United States, and internationally. It offers evaluation, planning, and designing infrastructure solutions; solutions for sustainable water resources, planning, management, and infrastructure; environmental services; integrated architecture, engineering, interior design, and planning solutions for buildings; and energy and resources solutions.
Featured Articles
- Five stocks we like better than Stantec
- Investing in Construction Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Invest in Biotech Stocks
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What Are Treasury Bonds?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Stantec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stantec and related companies with MarketBeat.com's FREE daily email newsletter.